Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
Clinical Characterization of Patients With Primary Biliary Cirrhosis Treated With Seladelpar in the Real-life Setting
The seladelpar registry will collect real-world data of patients with PBC diagnosis treated with seladelpar in the real-life scenario in Germany and Switzerland.
The seladelpar registry will offer data acquisition at weeks 0 - 4 - 8 - 12 - 24 - 36 - 48 of seladelpar treatment. Patients can be recruited either retro- or prospectively. The seladelpar registry will be an interim project until the start of the PBC 2.0 registry. Patients within the seladelpar registry will be characterized in detail with drug specific aspects, before it will be offered to transfer data for a long-term follow-up in the German PBC 2.0 registry if patients agree to this procedure in an upcoming informed consent process once the PBC 2.0 registry will be initiated.
Inclusion Criteria:
Exclusion Criteria:
johannes.wiegand@medizin.uni-leipzig.de0049 341 97 12330
Berlin, 12200, Germany
marion.muche@charite.de
Berlin, 13359, Germany
Frankfurt, 60590, Germany
Hanover, 30625, Germany
Heidelberg, 69120, Germany
Herne, 44623, Germany
Homburg, 66421, Germany
Jena, 07747, Germany
Kiel, 24105, Germany
Leipzig, 04103, Germany
München, 81675, Germany
t.mueller@drk-kliniken-berlin.deProf. Dr.
kathrin.sprinzl@unimedizin-ffm.de
Peter.Buggisch@amedes-group.com
Bantel.Heike@mh-hannover.de
Theresa.Wenz@med.uni-heidelberg.de
hinz@gashinz@gastro-praxis-herne.de
Joern.Schattenberg@uks.eu
PHILIPP.REUKEN@med.uni-jena.de
holger.hinrichsen@gh-mvz-kiel.de
rguenther@1med.uni-kiel.deDr.
johannes.wiegand@medizin.uni-leipzig.de0049 341 97 12 330
kg.simon@gastroenterologie-leverkusen.de
Jens.Marquardt@uksh.de
Gerald.Denk@med.uni-muenchen.de
Marc.Ringelhan@mri.tum.de
Jonel.Trebicka@ukmuenster.de
Andreas.Weber@klinikum-nuernberg.de
Christoph.Berg@med.uni-tuebingen.de
CSarrazin@joho.de
andreas.kremer@usz.ch